Form 4: Phyllis Yale Reports Acquisition of Deferred Share Units in Bristol-Myers Squibb

Director Phyllis Yale reported the acquisition of deferred share units in Bristol-Myers Squibb on June 30, 2024.

Summary

• On June 30, 2024, Phyllis Yale, a director of Bristol-Myers Squibb, acquired 842.764 deferred share units.
• These units will be converted into shares of common stock upon settlement, which occurs when Yale ceases to be a director or at a previously specified future date.
• The price per unit was $41.53.
• Following the transaction, Yale beneficially owns 28,812.523 shares, including deferred compensation and reinvested dividends.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects a routine transaction of deferred share units, which is part of standard compensation practices for directors. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings in the company.

Key Dates